Skip to main content
. 2021 Mar 18;12:645718. doi: 10.3389/fimmu.2021.645718

Table 4.

Risk factors for herpes zoster, univariable analysis.

Variable (reference) Cox proportional hazards Univariable analysis
RR (95% CI) p-value
Gender (male) 0.834 (0.559–1.245) 0.374
Age (continuous) 1.012 (0.997–1.028) 0.125
Age ≥50 years 1.672 (1.120–2.495) 0.012
Age ≥60 years 1.355 (0.889–2.066) 0.158
Organ transplant (Heart) 0.003
Lung
Liver
Kidney
1.035 (0.579–1.850)
0.300 (0.159–0.565)
0.482 (0.297–0.783)
0.907
<0.001
0.003
VZV IgG pre-transplant (negative) 2.370 (0.585–9.611) 0.227
Valganciclovir CMV prophylaxis (no) 0.629 (0.430–0.922) 0.017
CMV prophylaxis (no) 0.041
Valganciclovir 3 months
Valganciclovir >6 months
0.603 (0.404–0.900)
0.669 (0.289–1.547)
0.013
0.347
CMV prophylaxis (no) 0.086
Valganciclovir 3 months
Valganciclovir 6 months
Valganciclovir 9 months
0.603 (0.405–0.900)
0.752 (0.302–1.872)
0.430 (0.059–3.115)
0.013
0.540
0.403
Valganciclovir prophylaxis CMV R+ (no) a 0.550 (0.337–0.898) 0.017
CMV-PCR >1,000 IU/ml 1.012 (0.627–1.634) 0.960
Induction therapy (no) 1.676 (1.114–2.522) 0.013
Induction therapy (no) 0.035
Basiliximab or Rituximab
rATG
1.537 (0.952–2.482)
1.818 (1.144–2.887)
0.078
0.011
Induction therapy (no) 0.059
Basiliximab
rATG
Rituximab
1.484 (0.909–2.423)
1.817 (1.144–2.886)
2.432 (0.746–7.928)
0.114
0.011
0.140
Anti-rejection therapy (no)
Methylprednisolone
r-ATG

0.531 (0.311–0.906)
1.301 (0.629–2.691)
0.042
0.020
0.477
r-ATG anti-rejection therapy (no) 1.481 (0.720–3.050) 0.286

VZV IgG, varicella zoster virus specific immunoglobulin G; CMV, cytomegalovirus; r-ATG, rabbit anti-thymocyte globulin; CMV R+, CMV seropositive recipient.

a

CMV seropositive recipients without Valganciclovir prophylaxis were compared to CMV seropositive recipients with Valganciclovir prophylaxis.